Search Results

You are looking at 101 - 110 of 309 items for :

Clear All
Full access

Ioannis D. Papanastassiou, Kamran Aghayev, James R. Berenson, Meic H. Schmidt and Frank D. Vrionis

Almost 3 years ago, the International Myeloma Working Group published a statement and raised some questions regarding the treatment of cancer-related fractures with vertebral augmentation procedures (VAPs). Some of those issues included

Full access

Shanmugapriya b MS Li Yanli c MD, PhD Garcia Jacob c MD Lyman Gary H. e MD, MPH 11 2015 13 13 11 11 1383 1383 1393 1393 jnccn0131383 10.6004/jnccn.2015.0166 Multiple Myeloma, Version 2.2016 Anderson Kenneth C. MD Alsina

Full access

Renal Cell Carcinoma Outcomes East Carolina University; Enhancing Provider Education and Improving Healthcare Disparities in Chronic Myeloid Leukemia (CML) and Multiple Myeloma (MM) through a Rural Regional North Carolina Hospital Network

Full access

of Metastatic Breast Cancer Hematologic Malignancies Developments in the Treatment of Multiple Myeloma Guidelines for NHL: Updates to the Management of DLBCL and New Guidelines for T-Cell Lymphoproliferative Disorders Monitoring Molecular

Full access

(NCCN Guidelines): breast, non-small cell lung, ovarian, and prostate cancers, chronic myelogenous leukemia (CML), malignant pleural mesothelioma, melanoma, and multiple myeloma. Although all 8 NCCN Guidelines for Patients are available online on both

Full access

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn

1996 ; 46 : 108 – 111 . 39 Badros A Goloubeva O Dalal JS . Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature . Cancer 2007 ; 110 : 1042 – 1049 . 40 Jagannath S

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian and Maoko Naganuma

, an increased risk of VTE has been observed in certain hematologic malignancies, such as lymphoma, acute leukemia, and multiple myeloma. 1 , 41 , 42 Patients with high-grade lymphoma and acute promyelocytic leukemia seem to be at higher risk than

Full access

world-renowned experts for determining the best emerging techniques and practices for various blood cancers, including leukemia, lymphoma, and multiple myeloma. The virtual event will provide numerous opportunities for physicians, nurses, pharmacists

Full access

/Refractory Multiple Myeloma Beth Faiman, PhD, MSN, APRN-BC, AOCN, Cleveland Clinic Taussig Cancer Institute Clinical Updates and Issues: Advanced Non–Small Cell Lung Cancer Tracy Ruegg, MSN, CNP, AOCN, The Ohio State University Comprehensive Cancer Center

Full access

. A virtual learning platform for multiple myeloma is expected to launch in 2015. For more information about the NCCN 3D Virtual mCRC Simulator Learning Platform, visit NCCN.org . Free NCCN Pocket Guidelines Available for Antiemesis and